Get access

Immunohistochemical expression of somatostatin receptor subtypes 2 and 5 in colorectal cancer

Authors


Michael Koutsilieris, MD, PhD, Department of Experimental Physiology, Medical School, University of Athens, 75 Micras Asias Street, Goudi–Athens, 11527, Athens, Greece. Tel.: +30 210 7462597; fax: +30 210 7462571; e-mail: mkoutsil@med.uoa.gr

Abstract

Eur J Clin Invest 2012; 42 (7): 777–783

Abstract

Background  To determine the immunohistochemical expression levels of the somatostatin receptor subtypes 2 and 5 (Sst2 and Sst5) in patients with colorectal cancer (CRC) and to investigate the association of Sst2 and Sst5 expression with clinicopathological parameters.

Materials and methods  A retrospective analysis of formalin-fixed and paraffin-embedded CRC surgical specimens from 81 patients assessed by immunohistochemistry for Sst2 and Sst5 expression.

Results  Sst2 and Sst5 expression levels showed significant, negative association with CRC invasion and liver metastasis (P values < 0·05) while Sst2 also showed significantly increased expression in lower-grade tumours as well as in tumours located in the rectum (P values < 0·05). Patients with CRC expressing either Sst2 or Sst5 had significantly longer survival rates (P values < 0·05), although Sst expression was not found to be an independent predictor of survival after controlling for other known prognostic clinicopathological variables (P values > 0·05).

Conclusions  The present data confirm the relationship of Sst2 and Sst5 expression levels with reduced tumour aggressiveness.

Get access to the full text of this article

Ancillary